Skip to main content

Table 2 Demographic data and baseline characteristics of the study population addressed to severity, frequency and current preventive and abortive medication

From: Saliva molecular inflammatory profiling in female migraine patients responsive to adjunctive cervical non-invasive vagus nerve stimulation: the MOXY Study

Patient No.

Migraine type

Number of attacks per month

Pain intensity (VAS) Score

Number of headache days per month

Prophylactic medication at baseline

Acute medication at baseline

1

CM+

10

7/10

18

None

TRIP + NSAD

2

EM+

12

5/10

12

ß-blocker + TCA

TRIP + NSAD

3

EM−

5

7/10

9

ß-blocker + TCA

TRIP

4

EM−

12

8/10

14

None

TRIP

5

CM+

16

8/10

26

None

TRIP

6

EM−

7

6/10

9

None

TRIP

7

EM+

2

8/10

8

None

TRIP + NSAD

8

EM−

11

7/10

12

None

NSAD

9

EM+

10

8/10

10

Magnesium

TRIP + NSAD

10

EM+

3

8/10

3

SSRI

TRIP + NSAD

11

EM+

8

8/10

14

ß-blocker + TCA

TRIP

12

EM−

10

9/10

14

ß-blocker

TRIP + ASS

  1. f female, VAS visual analogue scale, CM chronic migraine, EM episodic migraine, ± with/without Aura, TRIP triptans, TCA tricyclic Antidpressants, SSRI Selective Serotonin reuptake inhibitor, NSAD nonsteroidal anti-inflammatory drugs, ASS acetylsalicylic acid, nVNS cervical non-invasive vagus nerve stimulation, preVNS medication remained stable 4 weeks prior to study enrollment (see inclusion criteria)